Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
AH Bio Fund I, L.P. - 30 Sep 2025 SCHEDULE 13G/A Report for CAMP4 THERAPEUTICS CORPORATION Common Stock, par value $0.0001 per share (CAMP)
- Filing manager
- AH Bio Fund I, L.P.
- Reporting owner
- Marc L. Andreessen
- Beneficially owned shares
- 2,125,339 shares
- Large-stake signal
-
Ownership
4.5%Beneficial ownership of this reported class.
Shares
2,125,339 sharesShares beneficially owned as disclosed.
Event date
30 Sep 2025Date tied to the ownership event or amendment.
Accepted by SEC
14 Nov 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 4.5%
- Symbol
- CAMP
- Shares outstanding
- 47,229,756 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 14 Nov 2025, 18:23:32 UTC
- Event date
- 30 Sep 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
AH Bio Fund I, L.P. disclosed 4.5% ownership in CAMP4 THERAPEUTICS CORPORATION Common Stock, par value $0.0001 per share (CAMP) on 30 Sep 2025.
Key facts
- AH Bio Fund I, L.P. filed SCHEDULE 13G/A for CAMP4 THERAPEUTICS CORPORATION Common Stock, par value $0.0001 per share (CAMP).
- Disclosed ownership: 4.5%.
- Date of event: 30 Sep 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 18:23.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (6)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| AH Bio Fund I, L.P. | 3.4% | 1,579,885 | 1,579,885 | 0 | /s/ Phil Hathaway | By AH Equity Partners Bio I, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 1) | |
| AH Equity Partners Bio I, L.L.C. | 3.4% | 1,579,885 | 1,579,885 | 0 | /s/ Phil Hathaway | By Phil Hathaway, Chief Operating Officer | |
| AH Bio Fund IV, L.P. | 1.2% | 545,454 | 545,454 | 0 | /s/ Phil Hathaway | By AH Equity Partners Bio IV, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 2) | |
| AH Equity Partners Bio IV, L.L.C. | 1.2% | 545,454 | 545,454 | 0 | /s/ Phil Hathaway | By Phil Hathaway, Chief Operating Officer | |
| Marc L. Andreessen | 4.5% | 2,125,339 | 0 | 2,125,339 | /s/ Phil Hathaway | Phil Hathaway, Attorney-in-Fact for Marc L. Andreessen (See Note 3) | |
| Benjamin A. Horowitz | 4.5% | 2,125,339 | 0 | 2,125,339 | /s/ Phil Hathaway | Phil Hathaway, Attorney-in-Fact for Benjamin A. Horowitz (See Note 3) |
CIK / CUSIP context first